Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents.

Dongke YuShi-Ying CaiAlbert MennonePamela VigJames L Boyer

Published in: Liver international : official journal of the International Association for the Study of the Liver (2018)

Multitargeted therapy is an important paradigm for treating cholestatic liver injury. The combination of CVC with atRA or other FXR activators may warrant a clinical trial in patients with cholestatic liver disease.

Keyphrases

liver injury
drug induced
clinical trial
open label
stem cells
randomized controlled trial
phase ii
cell therapy